John Kutz
Senior Partner, EVERSANA MANAGEMENT CONSULTING
Expertise:
John Kutz, Senior Partner at EVERSANA MANAGEMENT CONSULTING, is a life sciences professional who has spent the last 20 years of his career helping clients launch new products, develop leading-edge marketing capabilities, and develop strategies to reinvigorate growth.
Previously, John served as advisor to Arcus Biosciences on launch excellence and developed the commercialization blueprint for the organization, which is focused on oncology combination therapies. Prior to his work with Arcus, John was a Managing Director with Deloitte Life Sciences where he led the Google marketing alliance, developed client accounts, and delivered professional services projects focused on launch excellence, digital transformation, corporate strategy, brand positioning, and consumer and provider marketing.
John has worked on long-term engagement with clients to support the complete launch of life sciences products from strategy formulation to integrated planning and launch management. He is also focused on the use of digital marketing and analytical tools to directly engage consumers and healthcare professionals using social platforms and effective advertising.
Articles by John Kutz
Harnessing the Commercial Promise of Prescription Drug Use-Related Software (PDURS)
The FDA’s draft guidance on Prescription Drug Use-Related Software (PDURS) offers pharmaceutical manufacturers a novel strategy to enhance a drug’s label by enabling an HCP to prescribe software alongside the drug at the HCP’s discretion. The new framework makes it easier than before to pair software with a medication to help patients manage complex dosing, monitor side effects, and access behavioral change support. For pharmaceutical companies, the benefits of developing a PDURS product include the potential for brand differentiation, improved patient adherence, and demand retention post loss of exclusivity (LOE). PDURS also unlocks a new go-to-market option for digital health software. Released in September 2023, the PDURS draft guidance details […]